Drug delivery technique makes cancer immunotherapy more effective
Researchers in the Institute for Molecular Engineering at the University of Chicago (IME) have developed a new way to target immunotherapies and deliver them directly to tumors.
After years of treatment and three relapses, CAR T-cell therapy offers hope for leukemia patient
Jacelyn Walsh, a 41-year-old mother of two, relapsed three times in her battle with acute lymphoblastic leukemia. After trying CAR T-cell therapy at UChicago Medicine, she has hope for the future.
New checkpoint inhibitor shows promise in clinical trial for non-Hodgkin’s lymphoma
A novel antibody plus rituximab can block the “don’t eat me” signal, enabling macrophages to devour cancer cells.
